7.5.1 NEW INVESTIGATOR RECRUITMENT The Cancer Center has been very successful in recruiting new faculty members since 2002 (57 new research members are identified in a table in section 6-^ Institutional Commitment). We are requesting developmental support for two recruitments. These recruitments are included in the Cancer Center Strategic Plan, the Medical School Dean's initiative, and the Cancer Center/AHC compact. Recruitments are performed in partnership with the appropriate academic departments;for the 57 recruitments from 2003-2007, the Cancer Center partners included 1.8 departments in seven colleges. GENETIC MECHANISMS OF CANCER USING MODEL ORGANISMS The development of mouse model organisms has been instrumental in our understanding of cancer etiology and progression. Dr. David Largaespada, using the novel sleeping beauty Iransposon system, has been at the forefront of "forward" genetics for identifying cancer genes. Dr. Largaespada's expertise in mouse models of disease is recognized by the Cancer Center as he leads our Mouse Genetics shared resource; One new faculty member in Cancer Genetics will be recruited. The candidate must have a Ph.D. or M.D., and an interest in cancer genetics, cancer gene function and identification, genornics, cancer susceptibility genes, or hereditary cancer. We are searching for a faculty member with modelprganism experience. School/Department: Medical School/Genetics, Cell Biology, and Development Recruitment lead;David Largaespada, Ph.D. MEDICAL ONCOLOGY LEADERSHIP POSITION. The growth in clinical faculty has been in solid tumor oncology. Drs. McGlave and Yee have recognized the need to recruit a new mid-career or senior level faculty member to provide academic leadership for these clinical investigators. The future of solid tumor oncology resides at the laboratory/clinical interface;any leader in this area will require a strong background in translational research. The desired candidate will be board certified in Medical Oncology. He or she will have experience and a career-interest in solid tumor oncology. Physician-scientists and clinical investigators with a research focus on translational studies would be appropriate recruits. The successful candidate will have a track-record of sustained national peer-reviewed funding. This solid tumor oncology leadership position will be supported by an endowed chair, and may include support for additional faculty recruits. Department: Medical School/Medicine Recruitment lead: Philip McGlave, M.D.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Minnesota Twin Cities
United States
Zip Code
Abbott, Kenneth L; Nyre, Erik T; Abrahante, Juan et al. (2015) The Candidate Cancer Gene Database: a database of cancer driver genes from forward genetic screens in mice. Nucleic Acids Res 43:D844-8
Yee, Douglas (2015) A tale of two receptors: insulin and insulin-like growth factor signaling in cancer. Clin Cancer Res 21:667-9
Daniel, A R; Gaviglio, A L; Knutson, T P et al. (2015) Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes. Oncogene 34:506-15
Upadhyaya, Pramod; Hecht, Stephen S (2015) Quantitative analysis of 3'-hydroxynorcotinine in human urine. Nicotine Tob Res 17:524-9
Patel, Yesha M; Stram, Daniel O; Wilkens, Lynne R et al. (2015) The contribution of common genetic variation to nicotine and cotinine glucuronidation in multiple ethnic/racial populations. Cancer Epidemiol Biomarkers Prev 24:119-27
Takahashi, Yutaka; Hui, Susanta K (2014) Fast, simple, and informative patient-specific dose verification method for intensity modulated total marrow irradiation with helical tomotherapy. Radiat Oncol 9:34
Cooley, Sarah; Weisdorf, Daniel J; Guethlein, Lisbeth A et al. (2014) Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia. J Immunol 192:4592-600
Chen, Liddy M; Ibrahim, Joseph G; Chu, Haitao (2014) Flexible stopping boundaries when changing primary endpoints after unblinded interim analyses. J Biopharm Stat 24:817-33
Landman, Sean R; Hwang, Tae Hyun; Silverstein, Kevin A T et al. (2014) SHEAR: sample heterogeneity estimation and assembly by reference. BMC Genomics 15:84
Gates, Leah A; Phillips, Martin B; Matter, Brock A et al. (2014) Comparative metabolism of furan in rodent and human cryopreserved hepatocytes. Drug Metab Dispos 42:1132-6

Showing the most recent 10 out of 319 publications